Russian interferon α-2b drug in the treatment of chronic hepatitis C
Abstract
Aim of investigation. To study efficacy and safety of domestic recombinant interferon α-2b Altevir® in combination to ribavirin in previously untreated patients with chronic hepatitis C (CHC).
Material and methods. Retrospective treatment results rating of 85 patients (49 men (57%) and 36 women (43%)) was carried out. All patients received 3 million IU per day of Altevir® subcutaneously and ribavirin (Ribapeg). Treatment duration was 48 wks for patients with 1-st genotype of hepatitis C virus (HCV) and 24 wks — for patients with 2nd and 3а HCV genotypes. Results. Aviremia in 24 wks after the end of therapy (sustained virologic response — SVR) has been achieved in 100% of patients with 2-st HCV genotype, in 95,8% patients with 3а HCV genotype and in 65,6% patients with 1b HCV genotype. The registered adverse effects, well-known for interferon α-2b therapy, as a rule, were mild or moderate, AVT cancellation was not required in any patient.
Conclusions. For patients with CHC with 2-st, 3а HCV genotypes and favorable prognosis of virologic response at combined AVT, including Altevir® and ribavirin, SVR frequency can reach 100 and 96% respectively. At AVT, including Altevir® and ribavirin to CHC patients with 1b genotype of HCV and favorable prognosis of virologic response, 66% SVR rate can be achieved.
About the Author
N. B. Kovaleva
State educational state-funded institution of higher professional education «Ural state medical university»
Russian Federation
Russian Federation
Kovaleva Nina B. — MD, assistant-professor, Chairs of internal diseases postgraduate medical education and professional retraining
620028, Yekaterinburg, Repina street, 3
References
1. Данилов Д. С. Механизмы формирования комплаенса и современные подходы к его оптимизации // Рос. мед. вести.— 2008. — Т. 13, № 4. — С. 11–24.
2. Ивашкин В. Т., Маевская М. В., Лапшин А. В., Павлов Ч. С. Стандартный интерферон в лечении больных хроническим гепатитом С // Рос. журн. гастроэнтерол. гепатол. колопроктол.— 2007. — Т. 17, № 1. — С. 14–19.
3. Ковалева Н. Б. Противовирусная терапия хронического гепатита С стандартным (Роферон-А) и пегилированным (Пегасис) интерфероном α-2а в комбинации с рибавирином // Клин. гепатология.— 2009.— № 2. — С. 12–14.
4. Корочкина О. В., Гейвандова Н. И. и др. Эффективность и безопасность препарата альтевир при лечении больных хроническим гепатитом С // Клин. перспективы гастроэнтерол. гепатол.— 2009.— № 4. — С. 1–7.
5. Шарапова Л. П., Соколов С. А. и др. Опыт ведения регистра больных хроническим вирусным гепатитом в Тюменской области: от учета заболеваемости к управлению инфекцией // Клин. гепатология.— 2010.—№ 4. — С. 12–17.
6. Ascione A., de Luca M., Tartaglione M. et al. Peginterfon alfa-2a plus ribavirin is more effective than peginterferon α-2b plus ribavirin for treating chronic hepatitis C virus infection // Gastroenterology.— 2010. — N 138 (1). — P. 116–122.
7. Glandeli G., Antonelli G., Fera G. et al. Biological and clinical significance of neutralizing and blinding antibodies to interferon-alpha during therapy for chronic hepatitis C // Clin. ExP. Immunal.— 1994. — N 97. — P. 4–9.
8. Lam N. P., Neumann A. U., Gretch D. R. et al. Dosedependent acute clearance of hepatitis C genotype 1 virus with interferon alfa // Hepatology.— 1997. — N 26. — P. 226–231.
9. Manns M. et al. Peginterferon α-2а plus ribavirin compared with interferon α-2b plus ribavirin for initially mild chronic hepatitis C a randomised trial // Lancet.—2001. — N 358. — P. 958–965.
10. Witthoeft T., Hueppe D., John C. et al. Эффективность и переносимость пегинтерферона α-2а или α-2b и рибавирина у больных хроническим гепатитом С в обычной клинической практике: исследование PRACTICE // Клин. гепатология.— 2010. — N 6 (1). — P. 24–31.
Review
For citations:
Kovaleva N.B. Russian interferon α-2b drug in the treatment of chronic hepatitis C. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(2):65-68. (In Russ.)
Views:
195
Email this article 
